Abivax SA is committed to upholding certain values and corporate philosophy. The company believes in innovative research and development in the field of immunology. Abivax SA aims to improve patients' lives through the discovery and development of novel treatments for viral and inflammatory diseases. They emphasize ethical conduct, integrity, and transparency in their operations. Abivax SA prioritizes patient-centricity, scientific excellence, and collaboration with various stakeholders to achieve their goals. By harnessing breakthrough technologies, Abivax SA strives to make a positive impact on global healthcare.

Abivax SA is primarily present in various countries and regions across the globe. The company has a significant presence in France, where it is headquartered. Additionally, Abivax SA has established a strong foothold in Europe, with operations in Belgium, Germany, Switzerland, and the United Kingdom. The company also has a growing presence in North America, including the United States and Canada. Furthermore, Abivax SA is actively expanding its reach in Asia, with a focus on countries such as Japan and South Korea. With its global presence, Abivax SA is well-positioned to leverage diverse markets and opportunities for its stockholders.

Some significant milestones achieved by Abivax SA include the successful completion of Phase 2b clinical trials for their drug candidate, ABX464, in ulcerative colitis patients. Abivax SA has also received regulatory approval to conduct a Phase 3 trial for ABX464 in patients with moderate to severe ulcerative colitis. Furthermore, the company has forged partnerships with renowned organizations, such as the Bill & Melinda Gates Foundation, to develop potential treatments for infectious diseases. These milestones demonstrate Abivax SA's dedication to advancing novel therapies and its ability to form strategic collaborations in the pursuit of improving global health.

Abivax SA, a leading biotech company, has an intriguing history and background. Founded in 2013 and headquartered in Paris, France, Abivax focuses on developing innovative therapies to combat viral diseases, inflammation, and cancer. The company's cutting-edge technology platform encompasses three major therapeutic areas: antiviral treatments, immune enhancement therapies, and targeted cancer therapies. Abivax's dedicated team of scientists and researchers work diligently to advance its product pipeline, which includes potential breakthrough treatments for HIV/AIDS, inflammatory bowel disease, and liver cancer. With its commitment to improving patient lives through groundbreaking medical solutions, Abivax SA stands at the forefront of innovative biotechnology.

The main competitors of Abivax SA in the market include leading biopharmaceutical companies such as Gilead Sciences, Inc., GlaxoSmithKline plc, and Novartis AG.

Abivax SA is primarily active in the biotechnology industry.

The business model of Abivax SA revolves around developing and commercializing innovative therapies to treat infectious diseases, inflammatory diseases, and cancer. Abivax SA focuses on identifying and targeting specific mechanisms of the immune system in order to develop effective treatments. By leveraging its proprietary technology platforms, Abivax SA aims to create differentiated therapeutic candidates with the potential to address unmet medical needs. Through strategic partnerships, clinical trials, and regulatory approvals, Abivax SA aims to bring its therapeutic innovations to patients worldwide.

KGV за Abivax в момента не може да бъде изчислено.

KUV за Abivax в момента не може да бъде изчислено.

AlleAktien качественият резултат за Abivax е 4/10.

очаквана Abivax оборотът е 41,46 млн. EUR.

очаквана Abivax печалба е -175,43 млн. EUR.

Abivax SA is a global biotechnology company specialized in researching and developing therapeutics for the treatment of viral infections, autoimmune diseases, and cancer. It is headquartered in Paris, France, with a branch in Montpellier. The company has a pipeline of products at various stages of development, focusing on the discovery and development of small molecule drugs and protein candidates that target the body's immune system to combat a wide range of diseases. Its core product in the viral infections field is ABX464, a new generation HIV therapeutic that specifically targets the process of viral egress. Phase IIb studies have shown that ABX464 is capable of significantly reducing viral load in HIV patients and sustainably improving the immune system. Abivax SA plans to proceed with Phase III studies for ABX464. Another product being developed by Abivax SA is ABX196, an immuno-oncology product that targets the activation of T-cells in the body. It is currently being tested in four different studies, including patients with liver cancer, pancreatic cancer, and advanced solid tumors. In the field of autoimmune diseases, Abivax SA also has interesting candidates in its pipeline. For example, ABX464 is also being used in studies for Crohn's disease, where it blocks the inflammatory process by inhibiting cytokine release. Abivax SA develops its products in close collaboration with international academic and industrial researchers, as well as strategic partners such as the Japanese pharmaceutical giant Daiichi Sankyo and the French company Sanofi. The business model of Abivax SA is structured to encompass a wide range of products and mechanisms of action. The company is able to address a variety of indications and disease states, making it an attractive partner for pharmaceutical companies specializing in the research and development of therapeutics. Abivax SA has an experienced management team composed of industry veterans with extensive experience in the biopharmaceutical industry. The company also has a strong financial base, including a recently completed capital increase of 60 million euros. Abivax SA is a company that continuously invests in the research and development of products to improve health. The company is committed to bringing innovative and effective medicines to the market that can help millions of people around the world lead better lives.

Abivax разпределя дивидента от 0 EUR на плащания годишно.

Дивидентата за Abivax в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Abivax е FR0012333284.

WKN на Abivax е A14UQC.

Тикерът на Abivax е ABVX.PA.

През последните 12 месеца Abivax изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Abivax да изплати дивиденда в размер на 0 EUR.

Дивидентната доходност на Abivax в момента е .

Abivax изплаща дивидент на тримесечие. Той се разпределя в месеците .

Abivax платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 EUR. Това съответства на дивидентна доходност от 0 %.

Abivax се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Abivax на 25.07.2025 г. в размер на 0 EUR, трябваше да притежавате акцията в портфейла си преди Ex-деня на 25.07.2025 г..

Последното дивидентно плащане беше извършено на 25.07.2025 г..

През година 2024 Abivax изплати 0 EUR под формата на дивиденти.

Дивидентите от Abivax се изплащат в EUR.